Zydus Lifesci.

CADILAHC28 Mar 2024
Pharmaceuticals
+5.65 (+0.57%)
Lowest Today
Highest Today
Today’s Open
Prev. Close
52 Week High
52 Week Low
To Invest in Zydus Lifesci.
Zydus Lifesci.
Pharmaceuticals
CADILAHC28 Mar 2024
+5.65 (+0.57%)
OverviewFundamentals
1D
1M
6M
1Y
5Y
All

Zydus Lifesci. - Share Price & Details

Lowest Today
987
Highest Today
1020.95
Today’s Open
998.85
Prev. Close
999.6
52 Week High
1030.15
52 Week Low
482.55
Traded Volume
Market Cap(Cr)
Avg Traded Price
1 Year return
107.52%
Upper Circuit
Lower Circuit
P/E TTM
37.86
P/B Ratio
6.97
Traded Value(Cr)
0.00
EPS TTM
26.55
Book value
Dividend
0.60%

Price Performance

1.37 %
1 Wk
7.77 %
1 M
46.50 %
3 M
107.52 %
1 Y
43.97 %
YTD

Traded Volume Movement

Technical Details

Support 3
952
Support 2
969
Support 1
988
Pivot Point :
1005
Resistance 1
1024
Resistance 2
1041
Resistance 3
1060

Reports

Peer Comparison

Scrip NamePriceDaily ChangeM.Cap (Cr)1 Year Returns %P/E (TTM)PB Ratio
Zydus Lifesciences Ltd
₹1,005.25(+5.65/0.57%)
1,005.25+5.65101,751.82107.5237.866.97
Cipla Ltd
₹1,494.65(+28.45/1.94%)
1,494.65+28.45120,672.8768.0236.704.66
Astrazeneca Pharma India Ltd
₹5,320.40(+0.65/0.01%)
5,320.40+0.6513,301.0059.2083.3920.31
Bliss GVS Pharma Ltd
₹112.65(-1.50/-1.31%)
112.65-1.501,179.3458.2617.281.21
Abbott India Ltd
₹26,946.00(+197.55/0.74%)
26,946.00+197.5557,260.2524.8049.9818.42
Amrutanjan Health Care Ltd
₹618.65(+7.45/1.22%)
618.65+7.451,788.564.1140.656.83

About Zydus Lifesciences Ltd

Zydus Lifesciences Ltd is in the Pharmaceuticals sector, having a market capitalization of Rs. 101751.82 crores. It has reported a sales of Rs. 2225.1 crores and a net profit of Rs. 450.4 crores for the quarter ended December 2018. The company management includes Pankaj R Patel, Pankaj R Patel,Sharvil P Patel,Mukesh M Patel,Nitin Raojibhai Desai,Dharmishta N Rawal,Apurva S Diwanji,Ganesh N Nayak,Bhadresh K Shah,Dhaval N Soni,Akhil A. Monappa,Upasana Konidela. (Zydus Lifesciences Ltd) among others.
Chairman
Pankaj R Patel
Registered office
Zydus Corporate Park S No 536,Khoraj Sarkhej-Gandhinagar H/W,Ahmedabad,Gujarat,382481
FAX :91-079-26868337/26862365/26862366
Background
Incorporation Year1995
Face Value₹1
Market Lot1

Latest News

Stupendous FY24 drives market cap of 25 cos by Rs 1 lakh crore
A stellar run by domestic equities in FY24 saw the market capitalization of 25 companies rise by atleast Rs 1 lakh crore in a year. Of this, 17 of them are part of benchmark Nifty 50.The Nifty has gained nearly 29% in FY24 and it also tested a lifetime high after a muted show in FY23.Robust corporate earnings, high capital investments by the government, strong domestic economic growth.
29 Mar 2024 | 11:43 AM
Buy or sell: Rajesh Palviya of Axis Securities recommends to buy, hold?
Stock Market News: Domestic equity benchmark indices, the Sensex and Nifty 50, finished Thursday's session—the final trading day of the fiscal year 2024—with strong gains amidst favourable global cues. Nifty 50 zoomed around 30% in FY24, and Sensex surged about 28% in the same period. On Thursday, the 30-share BSE Sensex closed higher by 655.04 points or 0.90% at 73,651.35 level.
29 Mar 2024 | 11:02 AM
Short-term picks: Three stocks that may generate 17-25% returns
The Nifty 50 index has consistently displayed a bullish price structure, characterised by higher top, higher bottom formations, and is hovering near its all-time high levels on the monthly charts, indicating a strong positive sentiment for the long term. Recently, the index found significant support at the 13-week EMA (exponential moving average) and formed a notable Bullish Opening.
29 Mar 2024 | 10:01 AM
Three stocks to bet on for 17-25% return as bulls may rule Nifty
The Nifty 50 index has consistently displayed a bullish price structure, characterised by higher top, higher bottom formations, and is hovering near its all-time high levels on the monthly charts, indicating a strong positive sentiment for the long term. Recently, the index found significant support at the 13-week EMA (exponential moving average) and formed a notable Bullish Opening.
29 Mar 2024 | 11:07 AM
Buy or sell: Rajesh Palviya of Axis Securities recommends to buy, hold?
Stock Market News: Domestic equity benchmark indices, the Sensex and Nifty 50, finished Thursday's session—the final trading day of the fiscal year 2024—with strong gains amidst favourable global cues. Nifty 50 zoomed around 30% in FY24, and Sensex surged about 28% in the same period. On Thursday, the 30-share BSE Sensex closed higher by 655.04 points or 0.90% at 73,651.35 level.
29 Mar 2024 | 11:02 AM

How to buy Zydus Lifesci. shares on nse?

To buy Zydus Lifesci. shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified

What is the Zydus Lifesci. share price today?

The Zydus Lifesci. shares price on nse is Rs.1005.25 today.

What is the market cap of Zydus Lifesci. shares on BSE ?

The company has a market capitalization of Rs.101751.82Cr

What is the PE & PB ratio of Zydus Lifesci. shares ?

PE is 37.86 and PB is 6.97

What is the 52 Week High and Low of Zydus Lifesci. shares?

Zydus Lifesci. stock price high: Rs.1030.15 Zydus Lifesci. stock price low: Rs.482.55

What is Zydus Lifesciences' stock forecast?

With a new 52-week high, the Zydus Lifesciences stock is expected to outperform in the near term. The average target as of May 11, 2023, is Rs. 521 – a 1.41% increase from the current price of Rs. 513.75.

What is Zydus Lifesciences stock's highest price ever?

The highest price ever for Zydus Lifesciences was Rs. 650.50 on 4th June 2021. 

What is the Zydus Lifesciences stock price target for 2023?

The average stock target price of Zydus Lifesciences for 2023 is currently at Rs. 521 although some brokerages reckon it could go closer to Rs. 600. 

Does Zydus Lifesciences have a solid foundation?

Zydus Lifesciences has a solid foundation that has triggered its recent bullish run. It has a strong presence in the pharmaceutical industry and has been operating for several decades in the development, manufacturing, and marketing of a wide range of healthcare products, including pharmaceuticals, diagnostics, herbal products, and wellness products. With a recent FDA clearance on a pulmonary drug and better-than-expected Q3 profits, Zydus has shown stable and reliable growth. 

What is the Zydus Lifesciences stock dividend payout date?

Zydus Lifesciences is expected to pay its stock dividend in July. The company consistently paid dividends in July for the past two years.

What is the most recent Zydus Lifesciences stock news?

Zydus received the USFDA nod to manufacture and market drugs for osteoporosis, ulcer, blood pressure, heart disease, and pulmonary infections, and general anti-inflammatories. Furthermore, it is looking to sell its clinical research business for close to USD 200 million. 

setTimeout(function() { }, 5000);